We have investigated the potential for the p16-cyclin D-CDK4/6-retinoblastoma protein pathway to be exploited as a therapeutic target in melanoma. In a cohort of 143 patients with primary invasive melanoma we used fluorescence in situ hybridisation to detect gene copy number variations (CNVs) in CDK4, CCND1 and CDKN2A and immunohistochemistry to determine protein expression. CNVs were common in melanoma, with gain of CDK4 or CCND1 in 37% and 18% of cases respectively, and hemizygous or homozygous loss of CDKN2A in 56%.
Introduction
Over 197,000 cases of melanoma of the skin are diagnosed worldwide each year, resulting in 46,000 deaths annually (Ferlay et al., 2010) . While survival rates for early-stage disease are good (80-90%), new effective therapies are required for patients whose cancers progress and/or become metastatic. BRAF and NRAS are the most frequently mutated oncogenes in melanoma, with rates of 45-55% and 15% respectively (Curtin et al., 2005; Devitt et al., 2011; Hacker et al., 2010; Houben et al., 2004; Long et al., 2011) . The development and success of BRAF inhibitors in melanoma (Chapman et al., 2011; Flaherty et al., 2010) clearly indicates a prominent role of these oncogenes and oncogene addiction in this disease. We hypothesise that other oncogenic events are also critical to the development of melanoma and that potentially these events may induce dependence on individual oncogenes or key nodal points in pathways similar to BRAF or NRAS, which could create potential opportunities for targeted therapies. The
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p16-cyclin D-CDK4/6-retinoblastoma protein pathway (CDK4 pathway) is likely one such pathway that melanomas may be reliant on, given the high frequency of genomic alterations in this pathway (Curtin et al., 2005; Walker et al., 1998) and that these events can transform melanocytes (Sheppard and McArthur, 2013) .
Cyclin-dependent kinase 4 (CDK4) is a serine/threonine kinase that is a central regulator of the G1-S transition of the cell cycle. CDK4, or the highly homologous CDK6, when complexed with the D-type cyclins promotes cell cycle progression through the phosphorylation of several factors including the retinoblastoma protein. Subsequent phosphorylation of RB1 by the CDK2/CyclinE complex diminishes its ability to repress RNA polymerase I and III thus impacting on protein synthesis and in addition represses gene transcription through the E2F family of transcription factors that coordinate cell-cycle progression, nucleotide biosynthesis, DNA replication, mitotic progression, and DNA damage repair (Harbour et al., 1999; Lundberg and Weinberg, 1998; Sheppard and McArthur, 2013) . Further regulation occurs through a negative feedback loop whereby CDK4 (or CDK6) inactivation of RB1 relieves RB1 mediated repression of cyclin-dependent kinase inhibitor 2A (CDKN2A gene; p16 INK4A protein) (Li et al., 1994) , which in turn leads to a reduction in CDK4/6 activity. This feedback loop effectively works as a natural brake on activation of this pathway. Loss of p16 INK4A results in loss of the negative feedback control on this pathway leading to increased CDK4/6 activity that promotes cell cycle progression. It is also plausible that increasing activity of CDK4 by mutation or increased expression of its binding partner Cyclin D1 or CDK4 itself may overcome this negative feedback control and further activate the pathway. This process could potentially generate dependency on CDK4 for maintenance of cell proliferation.
The CDK4 pathway is known to be dysregulated in many cancers (Knudsen and Knudsen, 2008) and there is already strong evidence for a critical role of the CDK4 pathway in melanoma.
Sporadic human melanomas show high frequencies of genomic aberrations in CDKN2A, CDK4, and CCND1 by gene gain, loss or mutation (Curtin et al., 2005; Walker et al., 1998) . Inhibitory mutations in CDKN2A or activating mutations in CDK4 in the germline of humans leads to a 50-fold increase in the risk of developing melanoma (Hussussian et al., 1994; Kamb et al., 1994; Zuo et al., 1996) and this predisposition to melanoma is reflected in mouse models with loss of CDKN2A or activation of CDK4 (Hacker et al., 2006; Krimpenfort et al., 2001; Rane et al., 2002; Sharpless et al., 2001; Sotillo et al., 2001) . Taken together these data strongly indicate that melanocytes have a powerful predilection to be transformed by activation of the CDK4 pathway, and raises the possibility of oncogenic addiction to this pathway that could be therapeutically targeted and exploited.
The prominent role of CDK4 pathway activation in cancer has led to the development of inhibitors of CDK4/6 suitable for clinical evaluation. PD0332991 is the most advanced in clinical development, with studies to date showing the compound to have favourable pharmacokinetics, absence of significant off-target toxicities (Fry et al., 2004) and importantly, evidence of target modulation in vivo in humans (Leonard et al., 2012) . In this study we assessed gene copy number and protein levels for key members of the CDK4 pathway in a large clinical cohort of primary melanoma. In addition, and given the preclinical data indicating that melanoma formation and progression may be dependent on the CDK4 pathway we assessed the sensitivity of a panel of melanoma cells to the specific CDK4/6 inhibitor PD0332991 and correlated this with specific changes in this pathway. These studies are aimed at assessing PD0332991 as a potential novel therapeutic for the treatment of melanoma and identifying a potential target patient population for focussed clinical development of CDK4 inhibitors.
Results
Frequency of individual gene copy number variations of CDK4, CCND1 and CDKN2A and the relationship to patient outcome and both BRAF and NRAS mutation status Gene copy number variations (CNVs) for CDK4, CCND1 and CDKN2A were evaluated via fluorescence in situ hybridization (FISH) assay (Table 1 and Figure 1) . Gain of CDK4 copy number was found in 37% (30/81) of cases, with an average gene copy number of 3.14 (range 2.40 -6.76) for gain compared to 1.79 (range 1.50 -2.10) for normal. Gain of CCND1 was seen in 18% (22/121) of cases with an average gene copy number of 4.20 (range 2.42 -9.66) for gain compared to 1.69 (range 1.38 -2.27) for normal. Loss of CDKN2A was identified in 56% (63/113) of cases, with 50% (57/113) having hemizygous loss and 5% (6/113) having homozygous loss. The 57 cases with hemizygous loss had an average gene copy number of 0.80 (range 0.38-1.34) compared to 1.61 (range 1.32 -2.06) for normal. Individual CNVs were more common in wild type than NRAS and BRAF mutated melanomas ( Table 2 ). Gain of CCND1 was rarely seen together with BRAF mutations (4/121) whereas CDK4 gain (4/81) or CDKN2A loss (10/113) occurred infrequently together with NRAS mutations. We had complete follow up data for 131/143 patients, with median follow up time of 6 years and 6 months. Thirty-five patients had died, 27 due to melanoma. No significant interactions were found for individual gene CNVs and melanoma specific survival (Figure 2A -C). Mutations in BRAF or NRAS are known to confer poor survival in melanoma (Houben et al., 2004; Long et al., 2011) . When patients were stratified by BRAF or NRAS mutation status, individual CNVs did not alter survival outcomes (data not shown). With regards to clinical and pathological variables known to be prognostic in melanoma, including Breslow thickness, ulceration, regression and mitotic rate, we found that individual CNVs in the CDK4 pathway did not further stratify patient survival (Table 1) .
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Frequency of multiple gene copy number variations and the relationship to patient outcome and both BRAF and NRAS mutation status Sixty-eight cases were evaluated for all three genes ( (Table 3 ). When analysing combinations of gene CNVs with regards to patient outcome, we found that a gain of CCND1 in combination with a gain in CDK4 and/or loss of CDKN2A led to significantly poorer survival (p<0.03) ( Figure 2D ). No other combinations showed an association with patient survival. Our results suggest that single CNVs are more common in patients that are wild type for BRAF or NRAS (58% wild type; 35% BRAF mutation; 30% NRAS mutation), while multiple CNVs are more common in BRAF or NRAS mutant tumors (11% wild type; 40% BRAF mutation; 40% NRAS mutation; Table 3 ), although the number of patients in each group is relatively small.
Protein expression of CDK4, Cyclin D1 and p16 INK4A in primary invasive melanoma
Results for protein expression for Cyclin D1 and p16 INK4A were obtained for 130 and 132 cases respectively. We were unable to reliably optimise and validate immunohistochemistry for CDK4. 
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This article is protected by copyright. All rights reserved. expression of Cyclin D1 or p16 INK4A did not stratify patients, and expression was similar across wild type, BRAF and NRAS mutant tumors (data not shown).
Melanoma cell line sensitivity to PD0332991
The high frequency of gene alterations observed in the CDK4 pathway in primary melanoma led us to determine the ability of PD0332991 (Fry et al., 2004) , a CDK4/6 specific inhibitor, to inhibit cell proliferation in a panel of 47 melanoma cell lines. Figure 3A shows the concentration of PD0332991 that inhibited cell proliferation by 50% (GI50), with GI50s ranging from 30nM to 9µM. The majority of cell lines (37/47) were sensitive to PD0332991 and there was a clear separation between cells that responded to PD0332991 (having a GI50 less than 1µM) and those cells that were resistant. Proliferation rates for a subset of melanoma cell lines was determined and this did not correlate with sensitivity to PD0332991 (Supplementary Figure 3) . Examination of the images generated from the dose response curves indicated that PD0332991 was having a cytostatic effect rather than inducing cell death (data not shown), and cell cycle analysis on a subset of sensitive cells confirmed this, demonstrating that PD0332991 induced a G0/G1 cell cycle arrest and little if any cell death (Supplementary Figure 2) .
Genomic predictors of PD0332991 sensitivity
To assess how changes in the CDK4 pathway may impact on sensitivity to PD0332991 we gathered information from COSMIC, Cancer Cell Line Encyclopedia and published papers (Barretina et al., 2012; Dutton-Regester et al., 2012; Forbes et al., 2011; Stark and Hayward, 2007) and, in addition, sequenced all wild type and mutant p16 INK4A cell lines to confirm their status (Table 4) 
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This article is protected by copyright. All rights reserved. p<0.02). Of the 4 cell lines that had a R24C activating mutation in CDK4, 3 of these were sensitive to PD0332991 indicating that this mutation may also confer sensitivity. Mutations in BRAF and NRAS were found in 70% and 13% of cells respectively, and did not correlate with PD0332991 sensitivity. Together these data demonstrate that activation of the CDK4 pathway either through loss of p16 INK4A or mutation in CDK4 confers sensitivity to PD0332991, which is consistent with the concept that melanoma with these genetic alterations become dependent on the CDK4 pathway.
Western Analysis of Retinoblastoma 1 Protein and p16 INK4A
Previous studies in other cell types have indicated that loss of RB1 confers resistance to PD0332991 (Comstock et al., 2013; Dean et al., 2012; Fry et al., 2004; Konecny et al., 2011; Michaud et al., 2010 ) . To determine if RB1 loss was conferring resistance to PD0332991 in melanoma cells we performed western analysis on all the resistant cells and a subset of sensitive cell lines (Figure 4 ). All sensitive cell lines had detectable RB1 protein. Two resistant cell lines, A2058 and C013 had undetectable protein, consistent with resistance to PD0332991 being due to loss of RB1. Loss of functional p16 INK4A was associated with sensitivity to PD0332991, so we sought to determine if the cell lines that were both sensitive to PD0332991 and wild type for CDKN2A expressed p16 INK4A protein (Figure 4 ). Sixteen sensitive cell lines including all cells that were wild type for p16 INK4A were tested for p16 INK4A protein expression.
Of the seven cell lines that had no obvious CDKN2A gene deletion, methylation or mutation, all had detectable CDKN2A mRNA (data not shown) but only two had detectable protein (SK-MEL28 and C057). The loss of p16 INK4A expression in cell lines with CDKN2A mRNA suggests that in some cell lines loss of p16 INK4A occurs at either the translational or post-translational level. Of the two cell lines that did express p16 INK4A these cell lines had an activating mutation in CDK4. In contrast to the sensitive cell lines, all six resistant cell lines that were wild type for p16
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INK4A had detectable protein. These data further support the concept that loss of p16 INK4A protein and activation of the CDK4 pathway confers sensitivity to PD0332991.
Discussion
In the present study we show that in a large cohort of primary invasive melanomas gene alterations of the CDK4 pathway are common. Activating events in two key drivers of the CDK4 pathway, CDK4 and Cyclin D1 and loss of the key inhibitor p16 INK4A occurs in at least 75% of tumors, the most prominent being either hemizygous or homozygous loss of CDKN2A which occurs in 56% of tumors. These findings are in agreement with previous studies (Curtin et al., 2005) demonstrating amplifications of CCND1 and CDK4 are common and that loss of CDKN2A occurs in approximately 50% of cases. A gene gain in either CCND1 or CDK4 would likely increase signalling through the CDK4 pathway, and this signalling would be greatly amplified with the additional loss of the CDK4 inhibitor p16 INK4A , potentially leading to a more aggressive disease state. This hypothesis is supported by the observation that patients with CCND1 gain together with a loss of CDKN2A and/or a gain in CDK4 had a significantly poorer survival rate.
Our data suggest that this amplified CDK4 pathway signalling is a common early event in melanoma, is more common in tumors wild type for BRAF and NRAS, and that it may play a role in disease aggressiveness. Furthermore, it raises the possibility that in melanoma CDK4 pathway activation may provide an additional oncogenic addiction irrespective of BRAF and NRAS mutant status.
Given the prevalence of activating events in the CDK4 pathway in melanoma we assessed a melanoma cell line panel for sensitivity to the CDK4/6 inhibitor, PD0332991. We demonstrate that the majority of melanoma cell lines are sensitive to PD0332991. Consistent with the concept of CDK4 pathway dependent oncogene addiction, cell lines with loss of functional
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This article is protected by copyright. All rights reserved. INK4A protein, indicating that they are likely under chronic p16 mediated CDK4/6 inhibition. This chronic CDK4 inhibition likely renders them independent of this pathway for cell cycle progression and therefore resistant to CDK4/6 inhibition. These data suggest that p16 INK4A protein expression would be an excellent predictive response biomarker for PD0332991 in melanoma patients. Furthermore, this association between sensitivity to PD0332991 with loss of p16 INK4A expression has been previously reported for ovarian (Konecny et al., 2011) , breast (Finn et al., 2009 ) and renal cell carcinoma cell lines (Logan et al., 2013) indicating that it is likely a robust biomarker of sensitivity across many cancer types.
Melanoma cells that were RB1 null were also resistant to PD0332991. In agreement with our study, previous in vitro and in vivo studies on cell lines derived from breast and ovarian cancer and in glioblastoma multiforme tumors have clearly defined loss of RB1 as a key determinant of resistance to PD0332991 (Comstock et al., 2013; Dean et al., 2012; Fry et al., 2004; Konecny et al., 2011; Michaud et al., 2010 ) . With chronic loss of RB1 there is also loss of the negative feedback to p16 INK4A , thus causing a constant high level of p16 INK4A , as seen in our cell lines with RB1 loss (C013 and A2058; Figure 4 ). This high level of p16 INK4A would lead to chronic inhibition of CDK4/6 activity. Thus in RB1 null cells, through the high levels of p16 INK4A there is not only loss of CDK4/6 signalling to RB1 but also to other substrates involved in cell growth and proliferation therefore making it necessary for the cell to find other avenues to progress through the cell cycle (Sheppard and McArthur, 2013) .
Our data have shown a high frequency of copy number variations involving key CDK4 pathway genes CDK4, CCND1 and CDKN2A in primary invasive melanomas, indicating that these changes are an early event in melanoma. Similarly, our melanoma cell lines also demonstrated a high frequency of gene alterations in CDKN2A and CCND1. Furthermore, our PD0332991 response studies suggest that these changes do confer a state of dependence on the CDK4 pathway for cell cycle progression. As the melanoma progresses we predict that these events remain as potent drivers of CDK4 pathway activation and previous studies would indicate that at least the frequency of loss of p16 INK4A is more prevalent in advanced stages of disease (Sanki et al., 2007) .
Thus the present study provides the first evidence towards the use of CDK4 inhibitors in treating melanoma. We have potentially identified CDKN2A gene status or p16 INK4A protein expression as predictive biomarkers to select a sensitive patient population for efficacy of PD0332991 and conversely, RB1 loss, as a biomarker of resistance. In addition, the frequent activation of the CDK4 pathway across all melanomas irrespective of BRAF and NRAS mutation status and that these mutations do not alter sensitivity to the CDK4/6 inhibitor provides an opportunity for treating all melanoma patients with activation of the CDK4 pathway. Further work is required to elucidate the mechanisms of resistance to PD0332991 and to design rational combination therapeutic strategies that will improve outcomes for patients with primary invasive melanoma.
Methods

Patient cohort
The clinical and pathological characteristics for this patient cohort have been previously described (Handolias et al., 2010; Liu et al., 2007) . Table 1 .
Tissue Micro Arrays
Formalin fixed paraffin embedded (FFPE) tumor tissue blocks were obtained for 180 patients.
For each FFPE tumor block a section was cut and stained with Haematoxylin and Eosin for identification by a pathologist of areas of invasive melanoma. Of the initial 180 cases, 37 blocks were excluded as they showed no, or very little, invasive tumor component; 11 blocks were deemed to have insufficient invasive tumor area for inclusion on a tissue microarray (TMA); these cases had FISH and IHC performed on whole sections instead; 132 blocks had sufficient invasive tumor area for inclusion on TMAs. Up to four representative 1mm tumor cores were punched for each tumor block.
Fluorescence in situ hybridisation
FISH assays utilising FFPE tumor sections were optimised and validated for CDK4, CCND1 and CDKN2A. Four micron sections were cut onto superfrost+ slides, then deparaffinised in xylene and rehydrated through graded alcohols to water. Target retrieval was performed in Heat Pretreatment Solution (Invitrogen) either in a pressure cooker at 125 o C for 2 minutes (CCND1 and CDKN2A) or at 95 0 C for 30 minutes (CDK4), followed by several washes in water. Sections were treated with Enzyme Pretreatment Reagent (Invitrogen) for 20 minutes at room temperature (CCND1 and CDKN2A) or 30 minutes at 37C (CDK4). Slides were dehydrated through graded ethanol and air-dried. Probe (CDK4/SE12, Kreatech; CCND1/CEP11, Vysis; CDKN2A/CEP9, Vysis) was added to the sections, which were cover slipped and sealed with rubber cement to prevent evaporation during hybridisation. Slides were denatured for 5 minutes at 80 o C (CCND1 and CDKN2A) or 20 minutes at 85C (CDK4) then hybridised for 17
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This article is protected by copyright. All rights reserved. hours at 37 o C on a StatSpin Hybridiser (Dako). After hybridisation the coverslips were removed and slides were washed for 2 minutes in a 0.5x SSC stringent wash buffer at room temperature followed by 5 minutes in a 0.5x SSC stringent wash buffer at 75 o C. After several washes in water, sections were dried and mounted in Vectashield Mounting Medium with Dapi (Vector) and coverslipped. Sections were stored at 4°C in the dark prior to scoring.
Scoring of FISH was performed on an Olympus BX51 fluorescence microscope. For each tumor core or section areas of tumor cells were identified at low magnification using the DAPI filter.
Tumor areas were then scanned at high magnification (x100) to assess for heterogeneity of 
Immunohistochemistry
Four-micron FFPE sections from the TMA blocks were used for immunohistochemistry (IHC).
For p16 INK4A (clone E6H4; Cintec) and Cyclin D1 (clone SP4;Ventana) the fully automated Ventana Benchmark Ultra (Ventana) was used. After dewaxing, antigen retrieval was achieved using high pH Ventana CC1 retrieval solution for 32 minutes followed by incubation with p16 INK4A (antibody purchased pre-diluted) or Cyclin D1 antibody (1:100 dilution) for 32
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A pathologist performed scoring of IHC staining. The scoring system developed involved scores of 0-3 for both intensity of staining and proportion of tumor cells stained. For intensity scores were 0= negative, 1 = weak, 2 = moderate, 3 = strong. For proportion, scores were 0 = negative, 1 = 1-10%, 2 = 11-50%, and 3 = >50%. For each core, the intensity and proportion scores were added together to give a score out of six. A final score of 0 = negative, 2.0 -2.5 = weak, 3.0 -4.5= moderate, and >4.5 = strong. For tumor samples with more than one core on the TMAs, the highest score across all cores was used.
Melanoma Cell Lines
Melanoma cell lines were obtained from ATCC, NCI, DSMZ and from the Australasian Biospecimen Network-Oncology Cell Line Bank at the QIMR (Supplementary Table 1 ). PCR based short tandem repeat (STR) analysis using 6 STR loci was performed on early passage cell lines. This analysis confirmed the individuality of each cell line and then was used routinely to confirm the identity of cells. (6-acetyl-8-cyclopentyl-5-methyl-2-( (5-(piperazin-1-yl) pyridin-2-yl) amino) pyrido [2, 3-d] pyrimidin-7 (8H) -one) a specific CDK4 and CDK6 inhibitor (Fry et al., 2004) was obtained from Pfizer Oncology.
CDK4/6 inhibitor
PD0332991
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Mutation and copy number data
Genomic DNA was extracted using QIAGEN DNeasy Blood and Tissue kit. Information on the genomic alterations in CDKN2A, BRAF, NRAS, CDK4, CDK6 and CCND1 for each cell line shown in Table 4 was obtained from published data sets (Barretina et al., 2012; Dutton-Regester et al., 2012; Forbes et al., 2011; Stark and Hayward, 2007) and by sequencing CDKN2A as previously described. (Lim et al., 2013) .
Proliferation and Dose Response Assays
To assess the effects of PD0332991 on cell proliferation, cells were seeded in 96 well plates 48 hours prior to the addition of half-log10 doses of PD0332991 ranging from 1nM to 30µM or dimethylsulfoxide (DMSO) as vehicle control. Cell number was assessed using either the IncuCyte live cell imaging system (Essen Instruments) or using the standard sulforhodamine B (SRB) assay (Monks et al., 1991; Skehan et al., 1990) . In all experiments cells were plated so that the cell confluency at the end of the incubation was less than 90% in control (DMSO) treated wells. GI50 for PD0332991 was defined as the concentration of drug that induced a 50% decrease in cell number and was determined using GraphPad Prism (GraphPad Software).
For determination of doubling time for each cell line, cells were plated and cell number assessed every 4hrs -8hrs using the IncuCyte. Experiments were performed at least twice for each cell line and the average is shown.
Immunoblotting
Exponentially growing cells were lysed in RIPA buffer (50mM Tris, 100mM NaCl, 2mM EDTA, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, 50mmol/L sodium fluoride, 10mM sodium vanadate) plus phosphatase inhibitor cocktail (Roche). Protein concentrations were
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Statistical analysis
GraphPad Prism statistical software was used to calculate frequency of CNVs and for generation of Kaplan Meier plots for melanoma specific survival using a Log-rank (Mantel-Cox) test. Follow up was for an average of 6 years and 6 months. Melanoma specific survival was defined as death due to melanoma and excluded patients who died from other causes. Chi-square tests were used to assess associations between mutation status and sensitivity. Differences of p<0.05 were considered statistical significant. 
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Supplementary Figure 3-Proliferation rate and sensitivity to PD0332991. (A)
Proliferation rate was determined for a subset of exponentially growing melanoma cell lines.
Data shown are the average of at least two independent experiments. (B) Proliferation rate was plotted against the sensitivity to PD0332991. There was no significant correlation. 
Ulceration
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